Axsome Therapeutics (AXSM) Earnings Date & Reports

Key Takeaways

• Axsome Therapeutics (AXSM) is expected to report its third-quarter 2026 results in early November, with Wall Street consensus pointing to revenue near $257.5 million.
• Analysts project a narrower loss of roughly $0.49 per share, continuing the company's gradual march toward profitability.
• The newly approved AUVELITY indication for agitation associated with Alzheimer's disease is expected to be the quarter's dominant growth driver.
• Investors will closely track AUVELITY, SUNOSI, and SYMBRAVO prescription trends, along with selling, general, and administrative (SG&A) expense discipline.
• Pipeline updates, including the AXS-12 narcolepsy application and upcoming late-stage trial readouts, will shape the forward narrative.

Earnings Context and Why It Matters

Axsome Therapeutics is a commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders. Its quarterly earnings have become a key barometer of its transition from a clinical-stage developer into a diversified, revenue-generating neuroscience franchise. In the second quarter of 2026, total revenue rose 46% year over year to $218.4 million, powered by AUVELITY, which treats major depressive disorder (MDD). The April 2026 approval of AUVELITY for agitation in Alzheimer's disease added a major new market, making the upcoming report a crucial test of whether that launch momentum is translating into meaningful revenue acceleration for the broader business.

Earnings Expectations

Heading into the third-quarter 2026 report, consensus estimates compiled by financial data providers point to total revenue of approximately $257.5 million and a net loss of about $0.49 per share. This would mark a meaningful sequential step up from the $218.4 million reported in the second quarter and a continued narrowing of losses from the $0.99 per-share loss a quarter earlier.

Product-level performance remains the primary focus. AUVELITY generated $180.3 million in the second quarter (up 51% year over year), and its expansion into Alzheimer's disease agitation is expected to accelerate growth further. SUNOSI, approved for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea (OSA), contributed $35.8 million, while the migraine therapy SYMBRAVO delivered $2.3 million, a figure that fell short of some analyst expectations. Investors will watch whether SYMBRAVO regains momentum and whether AUVELITY's new indication lifts the overall top line.

AI Screener

For investors seeking to identify opportunities around earnings events and emerging biotech momentum, Tickeron's AI Screener offers a practical way to filter the market. This AI-powered stock and ETF (exchange-traded fund) discovery tool helps traders and investors scan thousands of securities based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can apply customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics to surface trade ideas, trending stocks, and breakout candidates more efficiently than manual screening. Explore the AI Screener to see how it can support your research process.

Market Reaction and Investor Sentiment

Sentiment around Axsome heading into the third-quarter report is shaped by a mix of commercial momentum and expense scrutiny. Shares have benefited from the AUVELITY label expansion, but the second-quarter report illustrated the sensitivity around costs: SG&A expenses climbed roughly 60% year over year to $208.1 million, and SYMBRAVO sales disappointed relative to consensus. As a result, investors will be weighing revenue acceleration against continued spending, with particular attention to whether management's assertion that SG&A has plateaued proves accurate. Commentary on the path to cash-flow positivity and on gross-to-net pricing dynamics for the commercial portfolio will be closely parsed for signs of improving operating leverage.

Forward Outlook and Key Factors to Monitor

The most important forward-looking variable is the trajectory of AUVELITY in Alzheimer's disease agitation, which management has described as a large, underpenetrated market. Prescription trends in both the new indication and the established MDD franchise will signal whether the expanded sales force, which grew to roughly 630 representatives, is converting demand into sustained revenue.

Beyond the quarter, several catalysts could reshape the outlook. The company's New Drug Application (NDA) for AXS-12 in narcolepsy has been accepted by the FDA (the U.S. Food and Drug Administration), with a Prescription Drug User Fee Act (PDUFA) target action date in May 2027. Top-line results from the Phase 3 ENGAGE trial in binge eating disorder are expected in the fourth quarter of 2026, and initiation of a Phase 2/3 trial of AXS-05 in smoking cessation was anticipated during the third quarter.

Investors should also monitor research and development (R&D) spending, which management has indicated will rise as new attention-deficit/hyperactivity disorder (ADHD) trials begin, against SG&A that is expected to stabilize. The balance between top-line growth, operating discipline, and pipeline execution will ultimately determine whether the company can sustain its momentum toward profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations